Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-25T18:16:44.981Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of psychosis in Parkinson's disease

Published online by Cambridge University Press:  02 January 2018

Denise Duncan  and
David Taylor
Denise Duncan
Affiliation:
The Maudsley Hospital Denmark Hill London SE5 8AZ
David Taylor
Affiliation:
The Maudsley Hospital Denmark Hill London SE5 8AZ
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Psychosis is often associated with Parkinson's disease. The cause of the psychosis cannot usually be confirmed but it may be due to disease progression or, more commonly, to the drugs used in the management of Parkinson's disease.

Type
Drug Information Quarterly
Information
Psychiatric Bulletin , Volume 20 , Issue 3 , March 1996 , pp. 157 - 159
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1996

References

Ellis, C. M., Lemmens, G., Parker, J., et al (1995) Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Neurology, 45(Suppl. 4) A251.Google Scholar
Factor, S. A., Brown, D., Molho, E. S., et al (1994) Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology, 44, 544–546.CrossRefGoogle ScholarPubMed
Ford, B., Lynch, T. & Greene, P. (1994) Risperidone in Parkinson's disease. Lancet, 344, 681.CrossRefGoogle ScholarPubMed
Meco, G., Alessandria, A., Bonifati, V., et al (1994) Risperidone for hallucinations in levo-dopa-treated Parkinson's disease patients. Lancet, 343, 1370–1371.CrossRefGoogle ScholarPubMed
Pfeiffer, C. & Wagner, M. L. (1994) Clozapine therapy for Parkinson's disease and other movement disorders. American Journal of Hospital Pharmacy, 51, 3047–3053.Google ScholarPubMed
Quinn, N. (1995) Drug treatment of Parkinson's disease. British Medical Journal, 310, 575–579.CrossRefGoogle ScholarPubMed
Rabey, J. M., Treves, T. A., Neufeld, M. Y., et al (1995) Low-dose clozapine in the treatment of levo-dopa-induced mental disturbances in Parkinson's disease. Neurology, 45, 432–434.CrossRefGoogle Scholar
Ray Chaudhuri, K., Abbott, R. J. & Millac, P. A. C. (1990) Subcutaneous apomorphine for Parkinsonian patients with psychiatric side-effects on oral treatment. Journal of Neurological and Neurosurgical Psychiatry, 54, 372–373.CrossRefGoogle Scholar
Wolters, E. C., Hurwtiz, T. A., Mak, E., et al (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology, 40, 832–834.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.